Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells

Dendritic cells (DCs) are antigen-presenting cells involved in T cell activation and differentiation to regulate immune responses. Lipoimmunogens can be developed as pharmaceutical lipoproteins for cancer immunotherapy to target DCs via toll-like receptor 2 (TLR2) signaling. Previously, we construct...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Kuan-Yin, Liu, Hsin-Yu, Yan, Wan-Lun, Wu, Chiao-Chieh, Lee, Ming-Hui, Leng, Chih-Hsing, Liu, Shih-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225995/
https://www.ncbi.nlm.nih.gov/pubmed/32231003
http://dx.doi.org/10.3390/cancers12040810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225995/
https://www.ncbi.nlm.nih.gov/pubmed/32231003
http://dx.doi.org/10.3390/cancers12040810

Ejemplares similares